Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bosker, Wendy M ^a   Karschner, Erin L ^b   Lee, Dayong ^b   Goodwin, Robert S ^b   Hirvonen, Jussi ^c   Innis, Robert B ^c   Theunissen, Eef L ^a   Kuypers, Kim P C ^a   Huestis, Marilyn A ^b   Ramaekers, Johannes G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DRONABINOL;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANNABIS SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; EDUCATIONAL STATUS; EYE TRACKING; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; RACE DIFFERENCE; SELECTIVE ATTENTION; SMOKING CESSATION; SOCIAL STATUS;

ADULT; ATTENTION; CANNABIS; CASE-CONTROL STUDIES; COGNITION; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; PSYCHOMOTOR PERFORMANCE; REPRODUCIBILITY OF RESULTS; TETRAHYDROCANNABINOL; TIME FACTORS; YOUNG ADULT;

CANNABIS;

EID: 84871760776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053127     Document Type: Article

References (33)

1. UNODC (2010) World drug report 2010. New York: United Nations Publications, Sales No. E.10.XI.13.
2. SAMHSA (2010) Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings: Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434). Rockville, MD.
3. EMCDDA (2010) Annual report 2010: the state of the drugs problem in Europe: Luxembourg: Publications Office of the European Union.
4. Solowij N, Battisti R, (2008) The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1: 81-98.
5. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, et al. (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287: 1123-1131.
6. Battisti RA, Roodenrys S, Johnstone SJ, Respondek C, Hermens DF, et al. (2010) Chronic use of cannabis and poor neural efficiency in verbal memory ability. Psychopharmacology (Berl) 209: 319-330.
7. Lorenzetti V, Lubman DI, Whittle S, Solowij N, Yucel M, (2010) Structural MRI findings in long-term cannabis users: what do we know? Subst Use Misuse 45: 1787-1808.
8. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D, (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58: 909-915.
9. Sim-Selley LJ, (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91-119.
10. Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, et al. (2006) Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 70: 986-996.
11. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, et al. (2011) Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol Psychiatry.
12. Pillay SS, Rogowska J, Kanayama G, Gruber S, Simpson N, et al. (2008) Cannabis and motor function: fMRI changes following 28 days of discontinuation. Exp Clin Psychopharmacol 16: 22-32.
13. Giuffrida A, Desarnaud F, Piomelli D, (2000) Endogenous cannabinoid signaling and psychomotor disorders. Prostaglandins Other Lipid Mediat 61: 63-70.
14. Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M, (1998) Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 5: 483-501.
15. Hunault CC, Mensinga TT, Bocker KB, Schipper CM, Kruidenier M, et al. (2009) Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) 204: 85-94.
16. Ramaekers JG, Theunissen EL, de Brouwer M, Toennes SW, Moeller MR, et al. (2010) Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl).
17. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, et al. (2006) Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug and Alcohol Dependence 85: 114-122.
18. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, et al. (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31: 2296-2303.
19. Ramaekers JG, Berghaus G, van Laar M, Drummer OH, (2004) Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 73: 109-119.
20. Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR, (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23: 266-277.
21. Bosker WM, Kuypers KPC, Conen S, Ramaekers JG, (2010) Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss. Psychopharmacology (Berl) 209: 69-76.
22. Kuypers KPC, Wingen M, Samyn N, Limbert N, Ramaekers JG, (2007) Acute effects of nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the night. Psychopharmacology (Berl) 192: 111-119.
23. Ramaekers JG, Conen S, de Kam PJ, Braat S, Peeters P, et al. (2011) Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl) 215: 321-332.
24. Wingen M, Bothmer J, Langer S, Ramaekers JG, (2005) Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 66: 436-443.
25. Ramaekers JG, Muntjewerff ND, Van Veggel LMA, Uiterwijk MMC, O'Hanlon JF, (1998) Effects of nocturnal doses of mirtazapine and mianserin on sleep and on daytime psychomotor and driving performance in young, healthy volunteers. Human Psychopharmacology-Clinical and Experimental 13: S87-S97.
26. Jex HR, McDonnell JD, Phatak AV (1966) A "critical" tracking task for man-machine research related to the operator's effective delay time. I. Theory and experiments with a first-order divergent controlled element. NASA CR-616. NASA Contract Rep NASA CR: 1-105.
27. Moskowitz H, (1973) Laboratory studies of the effects of alcohol on some variables related to driving. Journal of Safety Research 5: 185-199.
28. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA, (2007) Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A 1163: 318-327.
29. Milman G, Barnes AJ, Lowe RH, Huestis MA, (2010) Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A 1217: 1513-1521.
30. Pope HG Jr, Gruber AJ, Yurgelun-Todd D, (2001) Residual neuropsychologic effects of cannabis. Curr Psychiatry Rep 3: 507-512.
31. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, et al. (2009) Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 104: 2041-2048.
32. Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Herning RI, et al. (2009) Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol 33: 469-477.
33. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, et al. (2003) Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 69: 303-310.